G

GSK

Develops medicines, vaccines, and consumer health

Regional Sales Director

Full-Time
$186.8k - $311.3k/yr+ Annual bonus + Share-based long-term incentive program
Mid, Senior
Bachelor's, MBA
Boston, MA, USA+2 moreMore locations: Burlington, VT, USA | New York, NY, USA
In PersonUp to 50% travel, including overnight travel, is required.
Sales & Account ManagementField Sales

About the job

Requirements
  • A Bachelor of Arts or Bachelor of Science degree from an accredited institution is required.
  • A valid driver's license is required.
  • A minimum of 7 years of experience in pharmaceutical, medical, or related medical sales is required.
  • A minimum of 2 years of successful district or regional field management experience is required.
  • Experience leading teams in hospitals, health systems, and large practice groups is required.
  • Understanding of hospital decision-making processes, clinical pathways, formulary management, and antimicrobial stewardship programs is required.
  • The candidate must be willing to travel up to 50%, including overnight travel.
  • The candidate must be able to lift and/or move up to 35 pounds.
  • The candidate must adhere to all regulatory, legal, and compliance standards.
  • Proficiency in computer skills, including Microsoft Office, is required.
  • Strong analytical and technical abilities focused on customer service are required.
  • Exceptional presentation and selling skills, strong business acumen, and excellent oral and written communication skills are required.
Responsibilities
  • Lead and develop Account Managers to execute regional business plans, drive demand generation and appropriate product utilization, and achieve sales objectives compliantly.
  • Provide field leadership across a complex and matrixed commercial environment by partnering with sales leadership, commercial operations, marketing, market access, account management, and other cross-functional partners.
  • Translate national strategy into regional execution, monitor local market dynamics and team performance, and provide feedback on market conditions, customer insights, and marketing tactics.
  • Recruit, hire, coach, develop, and manage Account Managers to build a high-performing regional team.
  • Lead regional launch execution to drive awareness, demand generation, appropriate utilization, and sales performance for the launch product.
  • Develop and execute regional business plans that prioritize key accounts, customer segments, market opportunities, and resource allocation.
  • Provide effective leadership to the sales team to compliantly meet and exceed sales targets.
  • Execute the approved marketing plan with the regional team to maximize market penetration.
  • Identify and monitor local market conditions to build strong customer relationships and adapt strategies accordingly.
  • Ensure timely and effective delivery of marketing and sales tactics within the region.
  • Collaborate on goal setting and performance measures at all levels to ensure achievement.
  • Leverage data, dashboards, and performance insights to monitor business results, identify performance gaps, coach Account Managers, optimize execution, and guide resource allocation to achieve client and organizational objectives.
  • Set clear performance expectations, provide ongoing coaching and feedback, and manage performance and disciplinary matters to ensure accountability, compliance, and a high-performing team culture.
  • Conduct regular field ride-alongs with Account Managers to provide hands-on coaching.
  • Build a high-performing, accountable culture that drives achievement, engagement, development, and retention.
  • Ensure compliance with all field activities and company guidelines.
Desired Qualifications
  • Proven top-tier success leading high-performing hospital, specialty, or account-based sales teams in complex healthcare environments.
  • Demonstrated experience launching specialty, anti-infective, infectious disease, or hospital-based products with accountability for performance against launch objectives.
  • Deep understanding of hospital, health-system, and/or large practice group decision-making processes, including formulary management, antimicrobial stewardship programs, clinical pathways, protocol development, and demand generation.
  • Experience leading teams that engage multiple stakeholders, including clinical and non-clinical customers.
  • Strong account management leadership experience within integrated delivery networks, health systems, academic medical centers, and/or large group practice organizations.
  • Demonstrated ability to coach and develop account managers on strategic account planning, stakeholder mapping, business acumen, execution excellence, and driving sales.
  • Proven success working within highly matrixed organizations and leading coordinated execution across sales, market access, reimbursement, organized provider accounts, medical affairs, and marketing functions.
  • Experience translating access wins, formulary approvals, and protocol adoption into sustained product utilization and prescribing behavior.
  • Strong analytical skills with a track record of using data, account insights, and performance metrics to drive business results and resource allocation decisions.
  • Demonstrated excellence in building culture, talent development, and performance management during periods of rapid growth or launch readiness.
  • Anti-infective, hospital specialty, or infectious disease experience is strongly preferred.
  • Experience leading teams responsible for access enablement and/or demand generation activities across hospital accounts is preferred.
  • An MBA or advanced healthcare/business degree is preferred.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 28th, 2026
GSK Q3 sales rise 5% to $11.3B as specialty medicines drive growth, 2026 guidance reaffirmed

GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, driven by specialty medicines. Core operating profit rose 5%, while core earnings per share rose 1%. The company reaffirmed its 2026 guidance, expecting sales and core operating profit in the upper half of their ranges. Higher interest costs after the $10.6 billion Nuvalent acquisition will hold core earnings per share growth in the lower half of its range. Specialty medicines grew 15%, led by Cabenuva, up 35%. Vaccines sales fell 2% on Shingrix destocking in China. Research and development spending rose 22%. GSK has started 18 phase III studies this year and expects four more. It declared a third-quarter dividend of 17 pence per share.

Yahoo Finance
Oct 28th, 2026
GSK shares slide as pipeline doubts and weak vaccine sales offset $11.3B sales beat

GSK shares fell about 4% on October 28 despite a third-quarter sales and profit beat, as investors focused on pipeline doubts and weak vaccine sales, including shingles shot Shingrix. The stock fell as much as 7.3% earlier in the day. Core profit was 54.6 pence per share on turnover of £8.89 billion, against expectations of 50.4 pence and £8.84 billion. Specialty medicines for HIV, respiratory conditions and cancer rose 15%, but sales of new asthma drug Exdensur and vaccines missed forecasts. Chief executive officer Luke Miels is running a £1.9 billion ($2.5 billion) cost-savings plan to fund drug development ahead of patent losses. Market forecasts for 2031 sales of £36.64 billion trail GSK's target of more than £40 billion. GSK kept its annual outlook and took a £328 million restructuring charge in the quarter.

Yahoo Finance
Oct 28th, 2026
FTSE 100 slips 0.3% ahead of budget as GSK falls 4.3% and Unilever drops 3.4% despite earnings beats

British stocks fell on Wednesday as investors awaited the budget and weighed results from GSK and Unilever. The FTSE 100 was down 0.30% at 08:18 GMT, extending Tuesday's fall. GSK was the top loser, down 4.3%, despite beating third-quarter expectations. Core earnings per share were 54.6 pence against a consensus of 50.4 pence, and revenue was £8.89 billion. Unilever fell 3.38% even after it raised its volume growth forecast to at least 3%. Finance Minister John Healey said he would scrap gas standing charges, which cost the typical household £108 a year. Standard Chartered raised its full-year targets after third-quarter pretax profit jumped 27% to $2.25 billion. Brent futures rose 1.4% to $110.91 a barrel.

Yahoo Finance
Oct 28th, 2026
GSK holds guidance as specialty drugs lift sales 5% to $11.3B, but $417M charge cuts profit 16%

GSK kept its 2026 guidance after specialty medicines drove another quarter of growth, though a £328 million restructuring charge cut its profit. Sales rose 5% at constant exchange rates to £8.9 billion. Core operating profit rose 5% to £3.1 billion, while total operating profit fell 16% to £2.1 billion. The charge relates to Accelerate Growth, a cost-cutting programme that targets £1.9 billion of annual savings by 2029 at a total cost of £2.4 billion. GSK plans to put the savings mainly into research and development. Specialty medicines grew 15% to £3.9 billion, while vaccines fell 2% to £2.6 billion. Net debt rose to £20.7 billion from £14.5 billion at the end of 2025, after the $10.8 billion Nuvalent takeover. Chief executive Luke Miels said GSK had "delivered another strong quarter.

Yahoo Finance
Oct 27th, 2026
GSK's oncology push: Jemperli FDA approval and strong ADC data at ESMO for $97.4B group

GSK presented late-stage oncology data at the ESMO Congress in October 2026 on three drugs: Jemperli, Mo-Rez and Ris-Rez. The £76.7 billion pharmaceuticals group is leaning on oncology as a key part of its mix. The US Food and Drug Administration (FDA) granted Jemperli accelerated approval for MSI-H/dMMR locally advanced rectal cancer. In the AZUR-1 trial, 71% of patients received dostarlimab alone, without additional treatment or progression in the assessment window. Mo-Rez showed a 62% confirmed response rate in platinum-resistant ovarian and endometrial cancers, with a median duration of 12.2 months. Ris-Rez delivered a 61% objective response rate in extensive stage small cell lung cancer. Investors should watch the phase III trials and AZUR-1 follow-up data.